Use of the drug etodolac instead of drugs like Celebrex or Bextra could save the Veterans health-care system alone about $40 million annually.
"Since etodolac is available as a generic medicine, as much as an 80 percent cost savings can be achieved if patients were to use it rather than branded medications such as Celebrex or Bextra," said Dr. Byron Cryer, associate professor of internal medicine at UT Southwestern, a VA physician and senior author of the study published in the November issue of Gastroenterology. "In the 13 years of etodolac's use in the United States, there have been no reports of increases in cardiovascular events associated with this drug either." Etodolac is a non-steroidal anti-inflammatory drug (NSAID) in the same class as Celebrex. It was first released in the United States in 1991 as a pain reliever and arthritis treatment but has since gone off patent and is generically available.
In the study, Dr. Cryer and his colleagues at UT Southwestern and the Dallas VA evaluated more than 16,000 patients who, over a three-year period from 1999-2001, used either etodolac or naproxen, an over-the-counter pain reliever. Earlier studies indicated etodolac might be safer in the gastrointestinal tract, but none had evaluated its potential effects to reduce gastrointestinal ulcer complications such as bleeding.
When compared to naproxen, etodolac reduced rates of complication by more than 60 percent. This resulted in fewer hospitalizations for bleeding or perforated ulcers in patients taking NSAIDs.
Further, the decrease in ulcer complications with etodolac was as great as or greater than those seen in earlier studie
Contact: Scott Maier
UT Southwestern Medical Center